NZ598251A - 2-Arylamino-pyridopyrimidines and their uses, particularly in the treatment of cancer - Google Patents

2-Arylamino-pyridopyrimidines and their uses, particularly in the treatment of cancer

Info

Publication number
NZ598251A
NZ598251A NZ598251A NZ59825108A NZ598251A NZ 598251 A NZ598251 A NZ 598251A NZ 598251 A NZ598251 A NZ 598251A NZ 59825108 A NZ59825108 A NZ 59825108A NZ 598251 A NZ598251 A NZ 598251A
Authority
NZ
New Zealand
Prior art keywords
cancer
pyrimidine
tetrahydropyrido
pyrido
alkyl
Prior art date
Application number
NZ598251A
Other languages
English (en)
Inventor
Xian Shi
Yong Wang
Craig Stacy Takeuchi
Jeff Chen
Morrison B Mac
Original Assignee
Exelixis Patent Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Patent Co Llc filed Critical Exelixis Patent Co Llc
Publication of NZ598251A publication Critical patent/NZ598251A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ598251A 2007-03-14 2008-03-13 2-Arylamino-pyridopyrimidines and their uses, particularly in the treatment of cancer NZ598251A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91816007P 2007-03-14 2007-03-14
US96261707P 2007-07-30 2007-07-30
PCT/US2008/056883 WO2008112913A1 (en) 2007-03-14 2008-03-13 Inhibitors of the hedgehog pathway

Publications (1)

Publication Number Publication Date
NZ598251A true NZ598251A (en) 2013-06-28

Family

ID=39760053

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ598251A NZ598251A (en) 2007-03-14 2008-03-13 2-Arylamino-pyridopyrimidines and their uses, particularly in the treatment of cancer
NZ579480A NZ579480A (en) 2007-03-14 2008-03-13 2-Arylamino-quinazoline derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ579480A NZ579480A (en) 2007-03-14 2008-03-13 2-Arylamino-quinazoline derivatives

Country Status (18)

Country Link
US (3) US8222263B2 (enExample)
EP (2) EP2134695A4 (enExample)
JP (1) JP5577104B2 (enExample)
KR (1) KR20090130051A (enExample)
CN (1) CN101679308B (enExample)
AR (1) AR065767A1 (enExample)
AU (1) AU2008224941C1 (enExample)
BR (1) BRPI0808772A2 (enExample)
CA (1) CA2680796A1 (enExample)
CO (1) CO6231031A2 (enExample)
EA (1) EA018441B1 (enExample)
GE (1) GEP20135925B (enExample)
IL (1) IL200603A (enExample)
MX (1) MX2009009786A (enExample)
NZ (2) NZ598251A (enExample)
SG (1) SG179418A1 (enExample)
TW (1) TWI430798B (enExample)
WO (1) WO2008112913A1 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20110621T2 (hr) * 2006-09-15 2013-12-06 Pfizer Products Inc. SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
BRPI0808772A2 (pt) 2007-03-14 2014-08-12 Exelixis Inc Inibidores da via de hedgehog
WO2009010455A2 (en) * 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as modulators of metabotropic glutamate receptors
EP3190121B1 (en) 2007-12-27 2019-02-20 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction of cyclopamine 4-en-3-one derivative
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010009372A (es) * 2008-02-26 2010-09-22 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso.
ES2620027T3 (es) 2008-09-03 2017-06-27 Biomarin Pharmaceutical Inc. Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC
EP2440048B8 (en) 2009-06-09 2015-12-16 NantBioScience, Inc. Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
EP2440058A4 (en) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
SG178873A1 (en) * 2009-08-25 2012-04-27 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2576532B1 (en) * 2010-06-07 2018-07-18 Novomedix, LLC Furanyl compounds and the use thereof
EP2611796B1 (en) * 2010-09-01 2016-04-20 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN108707151B (zh) 2011-08-23 2022-06-03 阿萨纳生物科技有限责任公司 嘧啶并-哒嗪酮化合物及其用途
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013043255A1 (en) * 2011-09-21 2013-03-28 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
JP6250561B2 (ja) 2012-02-08 2017-12-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物およびそれらの使用方法
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CN105102000B (zh) 2012-11-01 2021-10-22 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
ES2664782T3 (es) * 2012-11-05 2018-04-23 Nantbio, Inc Derivados que contienen sulfonamida cíclica como inhibidores de la ruta de señalización de hedgehog
AU2013352256A1 (en) 2012-11-29 2015-06-18 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
CN103040824B (zh) * 2013-01-17 2015-05-27 四川大学 信号通路抑制剂及其制备方法和用途
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EP2958895B1 (en) 2013-02-20 2020-08-19 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
EP2970194A1 (en) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
KR20150132345A (ko) 2013-03-15 2015-11-25 바이오마린 파머수티컬 인크. Hdac 저해제
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN104177363B (zh) * 2013-05-24 2018-06-05 江苏先声药业有限公司 双环杂环胺类Hedgehog信号通路抑制剂
SG10201709926VA (en) 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2928658A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EA201691872A1 (ru) 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
NZ724691A (en) * 2014-03-24 2018-02-23 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
CN104230853B (zh) * 2014-08-18 2016-04-13 湖南华腾制药有限公司 一种(对甲苯基)甲胺-n-乙基吗啉盐酸盐的制备方法
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2976973A1 (en) * 2015-02-20 2016-08-25 Bayer Pharma Aktiengesellschaft N-phenyl-(morpholin-4-yl or piperazinyl)acetamide derivatives and their use as inhibitors of the wnt signalling pathways
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
AU2016271432A1 (en) * 2015-06-05 2017-12-07 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN110139692B (zh) 2016-11-22 2023-08-25 财团法人生物技术开发中心 用于调节刺猬途径的杂芳基胺化合物和其制法和用途
US20190008868A1 (en) 2017-04-28 2019-01-10 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
CN107082765A (zh) * 2017-06-07 2017-08-22 常州大学 一种2‑氯‑4‑苯基喹唑啉的合成方法
CA3074641A1 (en) * 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
EA202091186A1 (ru) * 2017-11-15 2020-10-01 Мирати Терапьютикс, Инк. ИНГИБИТОРЫ KRas G12C
WO2020005807A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CN115998742A (zh) * 2021-10-21 2023-04-25 澳门大学 一种bms-833923及其衍生物的应用及药物
CN116621722A (zh) * 2023-07-14 2023-08-22 甘肃帝邦升防水材料科技有限公司 超耐候柔性tpo自粘防水卷材及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6004979A (en) * 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6849634B2 (en) 2000-12-21 2005-02-01 Icagen Potassium channel inhibitors
US7105667B2 (en) * 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
HUP0402352A2 (hu) * 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
AU2004225977B2 (en) 2003-03-25 2011-03-24 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
WO2004087698A2 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
ES2290743T3 (es) * 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
US7524862B2 (en) * 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
WO2006078283A2 (en) * 2004-04-30 2006-07-27 Genentech, Inc. Quinoxaline inhibitors of hedgehog signalling
KR20160058972A (ko) * 2004-09-02 2016-05-25 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
EP1879881A2 (en) * 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
JPWO2006126718A1 (ja) 2005-05-27 2008-12-25 田辺三菱製薬株式会社 ピラゾロピリミジン誘導体
US7855194B2 (en) * 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
EP2034838A4 (en) * 2006-06-16 2012-01-04 Glaxo Group Ltd NOVEL CONNECTIONS
US20090318424A1 (en) * 2006-06-16 2009-12-24 Mauro Corsi Novel compounds
BRPI0808772A2 (pt) 2007-03-14 2014-08-12 Exelixis Inc Inibidores da via de hedgehog

Also Published As

Publication number Publication date
EP2527330A1 (en) 2012-11-28
US20090105211A1 (en) 2009-04-23
US8754092B2 (en) 2014-06-17
TWI430798B (zh) 2014-03-21
CA2680796A1 (en) 2008-09-18
AU2008224941A1 (en) 2008-09-18
US8222263B2 (en) 2012-07-17
EP2134695A1 (en) 2009-12-23
JP5577104B2 (ja) 2014-08-20
MX2009009786A (es) 2009-09-24
NZ579480A (en) 2012-03-30
SG179418A1 (en) 2012-04-27
CO6231031A2 (es) 2010-12-20
GEP20135925B (en) 2013-10-10
TW200843777A (en) 2008-11-16
US20120245139A1 (en) 2012-09-27
AR065767A1 (es) 2009-07-01
EP2134695A4 (en) 2011-05-25
IL200603A (en) 2014-08-31
JP2010521487A (ja) 2010-06-24
EA018441B1 (ru) 2013-08-30
IL200603A0 (en) 2010-05-17
CN101679308A (zh) 2010-03-24
EA200970856A1 (ru) 2010-04-30
WO2008112913A1 (en) 2008-09-18
US20120238570A1 (en) 2012-09-20
CN101679308B (zh) 2014-05-07
AU2008224941B2 (en) 2012-12-20
US8796294B2 (en) 2014-08-05
BRPI0808772A2 (pt) 2014-08-12
KR20090130051A (ko) 2009-12-17
AU2008224941C1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
NZ598251A (en) 2-Arylamino-pyridopyrimidines and their uses, particularly in the treatment of cancer
AU2018274043C1 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
RU2747260C2 (ru) Ингибитор рфрф4, способ его получения и его фармацевтическое применение
CA2647036C (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
Zheng et al. Synthesis, biological evaluation, and molecular docking studies of 2-chloropyridine derivatives possessing 1, 3, 4-oxadiazole moiety as potential antitumor agents
NZ626068A (en) Multicyclic compounds and methods of use thereof
US20160090382A1 (en) Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors
MX2010003445A (es) Derivados de nicotinamida, su preparacion y su uso terapeutico.
CN109020957B (zh) 作为mnk抑制剂的杂环化合物
NZ601453A (en) Protein kinase inhibitors
NZ619458A (en) Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway
Fallah-Tafti et al. Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities
KR20250002472A (ko) 질소 함유 삼중 축합고리 prmt5 억제제 및 이의 제조 방법 및 약학적 용도
MX2009010884A (es) 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k).
MX2010008363A (es) Derivados de arilamida diazepinopirimidona sustituidos para el tratamiento de enfermedades neurodegenerativas causadas por la actividad anormal de gsk3-beta.
WO2017139778A1 (en) Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
EP3414251A1 (en) Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
ES2968804T3 (es) Derivado de azaarilo, método de preparación del mismo y uso farmacéutico del mismo
IL197262A0 (en) Anti cancer use of caffeic acid and its derivatives
JP2023505239A (ja) 新規オーロラキナーゼ阻害剤およびその使用
KR20170035944A (ko) ＰＩ3Ｋ, ｍＴＯＲ 저해제로서 융합된 퀴놀린 화합물
US10106554B2 (en) 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs
AU2011340063A1 (en) Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
CA3093323A1 (en) Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof
CN103254133A (zh) 二芳基吡唑苯胺类化合物的制备及其在结肠癌治疗中的应用

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: EXELIXIS PATENT COMPANY LLC, US

Free format text: OLD OWNER(S): EXELIXIS, INC.

ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 1219138, MEYR, LISA E; 3074201, BAHCECI, SULEYMAN, 2355 HOLLAND STREET, SAN MATEO, CALIFORNIA 94403, US; 3074204, BAJJALIEH, WILLIAM, 2086 45TH AVENUE, SAN FRANCISCO, CALIFORNIA 94116, US; 3074208, CHEN, JEFF, 140 SOUTH VAN NESS AVENUE, APARTMENT 407, SAN FRANCISCO, CALIFORNIA 94103, US; 3074210, EPSHTEYN, SERGEY, 2922 SOUTHWYCKE TERRACE, FREMONT, CALIFORNIA 94536, US; 3074212, FORSYTH, TIMOTHY PATRICK, 1928 WINGATE WAY, HAYWARD, CALIFORNIA 94541, US; 3074214, HUYNH, TAI PHAT, 10 WATERSIDE PLAZA, #27E, NEW YORK, NEW YORK 10010, US; 3074216, KIM, BYUNG GYU, 10 DE SABLA ROAD, APARTMENT 801, SAN MATEO, CALIFORNIA 94402, US; 3074218, LEAHY, JAMES W., 1185 CAMEL

Effective date: 20130522

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3074201, BAHCECI, SULEYMAN, 2355 HOLLAND STREET, SAN MATEO, CALIFORNIA 94403, US; 3074204, BAJJALIEH, WILLIAM, 2086 45TH AVENUE, SAN FRANCISCO, CALIFORNIA 94116, US; 3074208, CHEN, JEFF, 140 SOUTH VAN NESS AVENUE, APARTMENT 407, SAN FRANCISCO, CALIFORNIA 94103, US; 3074210, EPSHTEYN, SERGEY, 2922 SOUTHWYCKE TERRACE, FREMONT, CALIFORNIA 94536, US; 3074212, FORSYTH, TIMOTHY PATRICK, 1928 WINGATE WAY, HAYWARD, CALIFORNIA 94541, US; 3074214, HUYNH, TAI PHAT, 10 WATERSIDE PLAZA, #27E, NEW YORK, NEW YORK 10010, US; 3074216, KIM, BYUNG GYU, 10 DE SABLA ROAD, APARTMENT 801, SAN MATEO, CALIFORNIA 94402, US; 3074218, LEAHY, JAMES W., 1185 CAMELLIA COURT, SAN LEANDRO,

Effective date: 20130522

S23 Proceedings under section 23: mention of inventor as such in patent

Free format text: INVENTOR BAHCECI, SULEYMAN, BAJJALIEH, WILLIAM, CHEN, JEFF, EPSHTEYN, SERGEY, FORSYTH, TIMOTHY PATRICK, HUYNH, TAI PHAT, KIM, BYUNG GYU, LEAHY, JAMES W., LEE, MATTHEW SANGYUP, LEWIS, GARY L., MAC, MORRISON B., MANN, GRACE, MARLOWE, CHARLES K., RIDGWAY, BRIAN HUGH, SANGALANG, JOAN C., SHI, XIAN, TAKEUCHI, CRAIG STACY, TESFAI, ZEROM, WANG, YONG ADDED

Effective date: 20130516

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 MAR 2015 BY CPAPAYMENTS

Effective date: 20131126

LAPS Patent lapsed